Plumbagin is a naphthoquinone found in the roots of Plumbago zeylanica. Here, we report an investigation to evaluate its antiobesity activity. The preliminary binding affinity of plumbagin to human pancreatic lipase (PL) was determined using molecular docking simulation. The in vitro PL inhibitory potential and the kinetics of inhibition were studied to validate and confirm the results obtained from molecular docking.
| INTRODUCTION
The roots of Plumbago zeylanica Linn. (Chitraka) have been described in ancient Ayurvedic texts to possess antiobesity and hypolipidemic activities (Kumari, Pushpan, & Nishteswar, 2013) . Furthermore, the aqueous extract of roots of P. zeylanica has shown promising antihyperlipidemic effect in rats (Pendurkar & Mengi, 2009 ) as well as in rabbits (Sharma, Gusain, & Dixit, 1991) . In the light of these observations, we evaluated the antiobesity potential of plumbagin, a naphthoquinone and one of the active constituents found in the roots of P. zeylanica. Plumbagin has been reported to have antiinflammatory, antimicrobial, anticancer, and antidiabetic activities (Panichayupakaranant & Ahmad, 2016) .
Pancreatic lipase (PL) is involved in the absorption of dietary lipids from the gastrointestinal tract. Therefore, inhibiting PL is one of the important strategies for combating obesity (Chatzigeorgiou, Kandaraki, Papavassiliou, & Koutsilieris, 2014) . Thus, the aim of this study was to determine the PL inhibitory potential of plumbagin. The preliminary binding affinity was computed using molecular docking simulation and validated by in vitro inhibition of PL. Furthermore, the effect of plumbagin on acute lipid absorption in rats, fed a high-fat diet, was also studied. The effects of plumbagin on in vitro adipocyte differentiation were investigated using 3T3-L1 cells.
| MATERIAL AND METHODS
3T3-L1 fibroblast cell line was obtained from National Centre for Cell Science, Pune, India. 3-Isobutyl-methylxanthine, insulin (from bovine pancreas), dexamethasone, porcine pancreatic lipase (Type II), p-nitrophenyl palmitate (p-NPP), thiazolyl blue tetrazolium bromide (MTT), and plumbagin were procured from Sigma Ltd., Bengaluru, India. Fetal bovine serum, Dulbecco's modified Eagle medium, and trypsin were procured from Gibco™, Thermo Fisher Scientific. Orlistat was provided as a gift sample by Macleods Pharma Pvt. Ltd., Mumbai, India.
Intralipid™ 10% (Fresenius-Kabi) was purchased from a local drug store whereas triglycerides (TG) kit was purchased from Erba Mannheim GmbH. All other chemicals used in the study were of analytical grade.
| Molecular docking
The binding affinity of plumbagin against porcine PL was estimated by molecular docking approach using GLIDE (Friesner et al., 2004) module in the Schrödinger suite. The X-ray crystal structures for human pancreatic lipase (PDB id: 1LPB; Egloff et al., 1995) and the porcine pancreatic lipase (PDB id: 1ETH) were imported from the protein data bank. The colipase chain and other heteroatoms, except the C11 alkyl phosphonate (MUP), were deleted. The X-ray structures were corrected using the Protein Preparation Wizard in the Schrödinger suite. This step composes of adding hydrogen atoms, assigning bond orders, assigning atom types according to the OPLS-2005 force field, and deleting water molecules beyond 5 Å from the ligand centre of mass. The protonation states for amino acid residues were generated using PROPKA at pH 7.4. Subsequently, the structures were minimized in vacuum using the restrained minimizer until the convergence criteria for heavy atom root-mean-squared deviation of 0.01 Å was achieved. The two X-ray structures were aligned using Maestro-GUI, and MUP coordinates from human PL were copied on the porcine PL. One more round of energy minimization was performed to clear any clashes that might have appeared during the coordinate transfer.
Plumbagin structure was prepared for docking using the LigPrep module in the Schrödinger suite.
The minimized complex was used to prepare the necessary files for molecular docking using GLIDE. Then MUP centre of mass was used to define the centre of the grid for docking. The van der Waals radii for ligand and protein atoms were scaled down by a factor of 0.8 to allow sufficient cushioning effect during molecular docking.
The hydroxy groups in serine, threonine, and tyrosine residues in the binding site were free to rotate to maximise the chance of forming hydrogen bonds between the ligand and receptor atoms. The docking protocol was validated by redocking MUP (cocrystallised ligand) starting from various random conformations generated using ConfGen module in the Schrödinger suite. The docking conformations were scored using the GLIDE standard scoring function, and the best conformation was selected on the basis of the GLIDE Emodel score.
| In vitro PL inhibition assay
In vitro PL inhibition assay was carried out using p-NPP as the substrate (Slanc et al., 2009) 
The IC 50 of plumbagin for PL was determined.
| Kinetics of PL inhibition by plumbagin
To determine the kinetics of inhibition of PL by plumbagin, the enzyme concentration was held constant (1 mg/ml) whereas the substrate (p-NPP) concentration was varied (0, 250, 500, 1,250, 2,500, 5,000, and 10,000 μM). Three concentrations of plumbagin (50, 100, and 200 μM) were incubated, each with the different concentrations of p-NPP as described for the determination of IC 50 . A Lineweaver-Burk plot was used to determine the type of inhibition (Wang et al., 2014) .
| Oral fat tolerance test
The protocol for the animal study was approved by the Institutional The rats were fasted overnight, and the next morning, blood was withdrawn (0 hr) from the retro-orbital plexus under light ether anaesthesia. The rats then received the different treatments as described above. Thirty minutes later, the rats were fed Intralipid™ orally and then blood was withdrawn after 1, 2, 3, 4, and 6 hr, serum was separated and used for the estimation of TG and the area under the curve of serum TG from 0 to 6 hr (Tamaru et al., 2013) .
2.5 | Cell culture and cell viability studies 3T3-L1 preadipocytes were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum in a carbon dioxide (5%) incubator maintained at 37°C. The cells were subcultured when they reached about 80-90% confluency.
Cell viability was measured using (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MTT) assay. The stock solution of plumbagin (1 mg/ml equivalent to 5,319.14 μM) was prepared in dimethyl sulfoxide (DMSO), and the concentrations used for the cell viability studies were diluted using 0.9% sodium chloride. The concentration of DMSO in the final dilutions was not more than 0.1%. 
| Oil red O staining and TG estimation
On the 10th day after differentiation of adipocytes, the cells were fixed with 10% formalin followed by staining with oil red O (ORO).
The plate was incubated for 30 min. The ORO was aspirated, and the stained cells were washed with isopropanol. The absorbance of the solution was read at 500 nm. For the estimation of TG, the cells were trypsinised, centrifuged, and the cell pellet was treated with lysis buffer (50 mmol/L Tris, 0.15 mol/L sodium chloride, 10 mmol/L ethylene diamine tetraacetic acid, 0.1% Tween-80, and adjusted to pH 7.5).
The TG contents of the cell lysate were determined using a commercially available kit. The TG content of the adipocytes was expressed as milligram per milligram protein (Mangal et al., 2017) .
| Statistical analysis
Data are represented as mean ± SEM. Statistical analysis was carried out using GraphPad Prism version 5, CA, USA using two-way analysis 
| Plumbagin inhibits PL in vitro through mixed type of inhibition
The IC 50 for plumbagin for porcine PL was found to be 82.08 ± 9.47 μM.
The inhibition was found to be of mixed type as seen from the The V max in the absence of plumbagin, 50, 100, and 200 μM of plumbagin were found to be 504. 54 ± 7.31; 387.79 ± 49.82; 302.54 ± 50.77; and 291.29 ± 27 .12 μM/min, respectively.
| Plumbagin inhibits lipid absorption in vivo after OFTT
Serum TG increased until 2 hr after Intralipid™ administration in all the groups. Plumbagin 1 mg/kg significantly reduced serum TG at 2, 3, 4, and 6 hr (p < .05) when compared with vehicle control. Treatment with orlistat significantly reduced serum TG compared with vehicle-treated group at 1, 2, 3, 4 (p < .01), and 6 hr (p < .05; Figure 1c ). The integrated area under the curve of serum TG from 0 to 6 hr for orlistat (p < .01) and PL-1 (p < .05) groups were also significantly reduced compared with vehicle-treated group (Figure 1d ).
| Effect of plumbagin on adipocyte viability and differentiation
Plumbagin at concentrations from 0.05-1.06 μM did not cause cytotoxicity when compared with untreated cells (cell control); however, it was found to be cytotoxic at 2.65 μM (Figure 2a ). Hence, we evalu- 
| DISCUSSION
The current work was embarked upon to investigate the antiobesity potential of plumbagin and to elucidate its mechanism(s) of action(s).
Inhibition of PL is known to be one of the relatively well-tolerated approaches, until date, for the treatment of obesity as demonstrated by the long-standing use of orlistat, vis-à-vis other antiobesity drugs that were withdrawn from the market owing to safety issues (Chatzigeorgiou et al., 2014) . Hence, we first determined the PL inhibitory potential of plumbagin. Preliminary clues were obtained from molecular docking studies, and it was seen that plumbagin possessed the necessary chemical groups to be identified as a binder of PL. However, there is a large scope to modify plumbagin to explore the large binding cavity for optimal interactions and tight binding. Nonetheless, we believe that plumbagin has shown promising results in the in silico studies that is validated experimentally in this current work. The V max decreased in a dose-dependent manner in the presence of plumbagin.
On the contrary, the k m increased in a dose-dependent manner in the presence of plumbagin. We further investigated the mechanism of inhibition, and it was found that plumbagin shows mixed type of inhibition as exemplified by the change in k m and V max of the enzyme in presence of the inhibitor (Cox & Nelson, 2008) . The PL inhibitory potential of plumbagin was corroborated in the in vivo studies in rats fed with Intralipid™. Thus, we provide compelling evidence that inhibition of PL is one of the mechanisms responsible for the antiobesity effect of plumbagin.
Hypertrophy of adipocytes is a hallmark of obesity, and molecules that can inhibit the differentiation of adipocytes are believed to act as potential antiobesity drugs (Virtue & Vidal-Puig, 2008) . Therefore, we investigated the effects of plumbagin on the differentiation of adipocytes in vitro using 3T3-L1 cells. Cell viability studies revealed that plumbagin was not cytotoxic up to concentration of 1.06 μM. Furthermore, plumbagin also reduced ORO staining and TG accumulation within the adipocytes, suggesting that it possesses antiadipogenic activity. Therefore, we conclude that plumbagin exhibits potential antiobesity effects by inhibiting PL as well as by inhibiting the differentiation of adipocytes. The effects of plumbagin on markers of adipocyte differentiation, fatty acid synthesis, lipolysis, and apoptosis warrant further investigation.
